AI play Healx raises $56M to repurpose drugs for rare disease

Bolstered by a $56 million series B round, Healx is taking human bias out of drug discovery by leaving most strategic and technical decisions up to AI. Its approach is to use an AI-powered platform to identify tractable rare diseases and drugs that could be repurposed to treat them.

The series B, announced Wednesday and led by Atomico, will help fund Healx Ltd.’s first clinical trial, a Phase IIa study for Fragile X syndrome. The trial, slated to start early next year, will test four undisclosed drugs identified through the company’s Healnet platform...